نتایج جستجو برای: egfr mutation

تعداد نتایج: 315266  

2015
Lin Yang Chuanhao Tang Bin Xu Weixia Wang Jianjie Li Xiaoyan Li Haifeng Qin Hongjun Gao Kun He Santai Song Xiaoqing Liu Ramon Andrade de Mello

OBJECTIVES Epidermal growth factor receptor (EGFR) gene mutations in tumors predict tumor response to EGFR tyrosine kinase inhibitors (EGFR-TKIs) in non-small-cell lung cancer (NSCLC). However, obtaining tumor tissue for mutation analysis is challenging. Here, we aimed to detect serum peptides/proteins associated with EGFR gene mutation status, and test whether a classification algorithm based ...

2015
Kenichi Suda Isao Murakami Kazuko Sakai Hiroshi Mizuuchi Shigeki Shimizu Katsuaki Sato Kenji Tomizawa Shuta Tomida Yasushi Yatabe Kazuto Nishio Tetsuya Mitsudomi

Lung cancers often harbour a mutation in the epidermal growth factor receptor (EGFR) gene. Because proliferation and survival of lung cancers with EGFR mutation solely depend on aberrant signalling from the mutated EGFR, these tumours often show dramatic responses to EGFR tyrosine kinase inhibitors (TKIs). However, acquiring resistance to these drugs is almost inevitable, thus a better understa...

2016
Basharat Ahmad Kasana Waseem Raja Dar Sheikh Aijaz Aziz Abdul Rashid Lone Najeeb Ullah Sofi Imtiyaz Ahmad Dar Muzamil Latief Faheem Arshad Moomin Hussain Mir Hussain

INTRODUCTION Lung cancer is one of the most common causes of cancer deaths worldwide. Adenocarcinoma is taking over squamous cell lung cancer as the predominant histological subtype. Several cytotoxic drugs are available for the treatment of lung cancer, but side effects limit their use. Recently, targeted therapies for cancers have come into clinical practice. AIMS AND OBJECTIVES To determin...

2014
Susana Benlloch Maria Luisa Botero Jordi Beltran-Alamillo Clara Mayo Ana Gimenez-Capitán Itziar de Aguirre Cristina Queralt Jose Luis Ramirez Santiago Ramón y. Cajal Barbara Klughammer Mariette Schlegel Walter Bordogna David Chen Guili Zhang Barbara Kovach Felice Shieh John F. Palma Lin Wu H. Jeffrey Lawrence Miquel Taron

The EURTAC trial demonstrated that the tyrosine kinase inhibitor (TKI) erlotinib was superior to chemotherapy as first-line therapy for advanced non-small cell lung cancers (NSCLC) that harbor EGFR activating mutations in a predominantly Caucasian population. Based on EURTAC and several Asian trials, anti-EGFR TKIs are standard of care for EGFR mutation-positive NSCLC. We sought to validate a r...

Journal: :Clinical lung cancer 2014
Koji Mochinaga Tomoshi Tsuchiya Toshiya Nagasaki Junichi Arai Tetsuro Tominaga Naoya Yamasaki Keitaro Matsumoto Takuro Miyazaki Atsushi Nanashima Tomayoshi Hayashi Kazuhiro Tsukamoto Takeshi Nagayasu

BACKGROUND It has been shown that 5-fluorouracil (5-FU) sensitivity in patients with non-small-cell lung cancer (NSCLC) is associated with epidermal growth factor receptor (EGFR) mutation status. However, the relationship between dihydropyrimidine dehydrogenase (DPD), a 5-FU degrading enzyme, and EGFR mutation status is unknown. Here, we focus on clinicopathologic factors and in vitro correlati...

2016
Yuli Wang Zhitao Guo Yang Li Qinghua Zhou

Individualized therapies targeting epidermal growth factor receptor (EGFR) mutations show promises for the treatment of non small-cell lung carcinoma (NSCLC). However, disease progression almost invariably occurs 1 year after tyrosine kinase inhibitor (TKI) treatment. The most prominent mechanism of acquired resistance involves the secondary EGFR mutation, namely EGFR T790M, which accounts for ...

2017
Chengjuan Zhang Bing Wei Peng Li Ke Yang Zhizhong Wang Jie Ma Yongjun Guo

OBJECTIVE Epidermal growth factor receptor (EGFR) specific mutations have been known to improve survival of patients with non-small-cell lung carcinoma (NSCLC). However, whether there are any changes of EGFR mutations after targeted therapy and its clinical significance is unclear. This study was to identify the status of EGFR mutations after targeted therapy and predict the prognostic signific...

2013
Hua Bai Zhijie Wang Yuyan Wang Minglei Zhuo Qinghua Zhou Jianchun Duan Lu Yang Meina Wu Tongtong An Jun Zhao Jie Wang

PURPOSE This study evaluated occurrence and potential clinical significance of intratumoral EGFR mutational heterogeneity in Chinese patients with non-small cell lung cancer (NSCLC). MATERIALS AND METHODS Eighty-five stage IIIa-IV NSCLC patients who had undergone palliative surgical resection were included in this study. Of these, 45 patients carried EGFR mutations (group-M) and 40 patients w...

2015
Yasushi Yatabe Keith M. Kerr Ahmad Utomo Pathmanathan Rajadurai Van Khanh Tran Xiang Du Teh-Ying Chou Ma. Luisa D. Enriquez Geon Kook Lee Jabed Iqbal Shanop Shuangshoti Jin-Haeng Chung Koichi Hagiwara Zhiyong Liang Nicola Normanno Keunchil Park Shinichi Toyooka Chun-Ming Tsai Paul Waring Li Zhang Rose McCormack Marianne Ratcliffe Yohji Itoh Masatoshi Sugeno Tony Mok

INTRODUCTION The efficacy of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in EGFR mutation-positive non-small-cell lung cancer (NSCLC) patients necessitates accurate, timely testing. Although EGFR mutation testing has been adopted by many laboratories in Asia, data are lacking on the proportion of NSCLC patients tested in each country, and the most commonly used testing me...

Journal: :Neoplasma 2008
Tsu-Hui Shiao Yih-Leong Chang Chong-Jen Yu Yeun-Chung Chang Ya-Chieh Hsu Shih-Han Chang Jin-Yuan Shih Pan-Chyr Yang

INTRODUCTION Knowledge about the current status of the epidermal growth factor receptor (EGFR) has resulted in an improvement in the treatment of non-small cell lung cancer. In contrast, small cell lung cancer (SCLC) continues to frustrate clinicians with its tendency toward early metastasis and chemotherapy resistance. Recent studies have reported the EGFR mutation and its response to gefitini...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید